Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells
© Habano et al; licensee BioMed Central Ltd. 2011
Received: 26 July 2010
Accepted: 22 February 2011
Published: 22 February 2011
Pregnane X receptor (PXR) is a key transcription factor that regulates drug metabolizing enzymes such as cytochrome P450 (CYP) 3A4, and plays important roles in intestinal first-pass metabolism. Although there is a large inter-individual heterogeneity with intestinal CYP3A4 expression and activity, the mechanism driving these differences is not sufficiently explained by genetic variability of PXR or CYP3A4. We examined whether epigenetic mechanisms are involved in the regulation of PXR/CYP3A4 pathways in colon cancer cells.
mRNA levels of PXR, CYP3A4 and vitamin D receptor (VDR) were evaluated by quantitative real-time PCR on 6 colon cancer cell lines (Caco-2, HT29, HCT116, SW48, LS180, and LoVo). DNA methylation status was also examined by bisulfite sequencing of the 6 cell lines and 18 colorectal cancer tissue samples. DNA methylation was reversed by the treatment of these cell lines with 5-aza-2'-deoxycytidine (5-aza-dC).
The 6 colon cancer cell lines were classified into two groups (high or low expression cells) based on the basal level of PXR/CYP3A4 mRNA. DNA methylation of the CpG-rich sequence of the PXR promoter was more densely detected in the low expression cells (Caco-2, HT29, HCT116, and SW48) than in the high expression cells (LS180 and LoVo). This methylation was reversed by treatment with 5-aza-dC, in association with re-expression of PXR and CYP3A4 mRNA, but not VDR mRNA. Therefore, PXR transcription was silenced by promoter methylation in the low expression cells, which most likely led to downregulation of CYP3A4 transactivation. Moreover, a lower level of PXR promoter methylation was observed in colorectal cancer tissues compared with adjacent normal mucosa, suggesting upregulation of the PXR/CYP3A4 mRNAs during carcinogenesis.
PXR promoter methylation is involved in the regulation of intestinal PXR and CYP3A4 mRNA expression and might be associated with the inter-individual variability of the drug responses of colon cancer cells.
Nuclear receptor families play a pivotal role in regulating genes involved in drug metabolism and disposition. Pregnane X receptor (PXR, also termed SXR, PAR, and NR1I2 as its gene name) is a crucial regulator of various phase I and phase II drug metabolizing enzymes and drug transporters. PXR is expressed in liver, small intestine and other organs. PXR, with a number of therapeutic drugs and other xenobiotics as its ligands, dimerizes with retinoid X receptor α (RXRα). The ligand-PXR-RXRα complex binds to promoter and enhancer elements located upstream of cytochrome P450s (CYPs) 3A and 2C family members, UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), glutathione S-transferases (GSTs), and ATP binding cassette (ABC) drug transporters (reviewed in [1–3]).
Wide inter-individual variability has been documented in the expression of hepatic CYP3A4 with respect to basal and PXR-inducible activities. The genetic variability of PXR and CYP3A4 is not sufficiently frequent to explain the apparent inter-individual variability . The inter-individual variability in basal hepatic CYP3A4 expression may include variability in PXR expression, as PXR is activated by endogenous steroid hormones and bile acids. Inter-individual variability of CYP3A4 expression is also observed in human intestine. Interestingly, a report using paired tissue samples of livers and small intestines indicated no observed correlation between the hepatic and small intestine CYP3A4 expression levels . Another research group reported that a majority of CYP3A4 resided in the proximal region of the small intestine, and that the CYP3A4 protein levels decreased dramatically in the distal small intestine . These observations suggest the CYP3A4 is regulated through tissue specific epigenetic regulation in normal tissue. The aim of the present study is to find possible and not yet fully elucidated mechanisms which regulate heterogeneous basal PXR and CYP3A4 expression and activity in cancerous tissues as well. Indeed, several studies previously found a fraction of genes that exhibited inter-individual differences in transcript levels associated with DNA methylation status [7, 8].
DNA methylation of the CpG-rich sequence around exon 3 of the PXR gene is involved in the epigenetic regulation of PXR in human neuroblastoma . However, epigenetic regulation of PXR and CYP3A4 in human gut is poorly understood. In order to determine whether epigenetic mechanisms function in PXR and CYP3A4 regulation and intestinal metabolism, we examined DNA methylation and mRNA expression of several candidate genes on the PXR/CYP3A4 regulatory pathway in human colon cancer cell lines and tissues.
Cell lines and tissue samples
Human colorectal cancer cell lines LS180, Caco-2, HT29, HCT116, DLD-1, LoVo, SW48 and SW620 were purchased from DS Pharma Biomedical Co., Ltd. (Osaka, Japan). LS180 cells were cultured in E-MEM medium (Invitrogen Corp., Carlsbad, CA) at 37°C under an atmosphere of 5% CO2. The other cells were cultured under conditions described elsewhere .
Eighteen pairs of cancerous and adjacent normal mucosa were excised from surgical specimens of colorectal cancers. The cancerous and normal epithelia were separated from stroma using crypt isolation . All samples were selected from the same series of cancers as we used in a previous study . All 18 patients with colorectal cancers did not receive chemotherapy before surgical resection. The study protocol was approved by ethics committee of Iwate Medical University (molecular analysis of gastrointestinal tumors and the surrounding mucosa; reference number, H21-140).
Treatment with 5-aza-2'-deoxycytidine
LS180, LoVo, Caco-2, HCT116, HT29 and SW48 cells were seeded at a concentration of 1 × 105 cells on a 100 mm dish. The next day, treatment of cells with 0, 0.5 or 5 μM 5-aza-2'-deoxycytidine (5-aza-dC) (Sigma Chemical, St. Louis, MO) was started, and 5-aza-dC was removed by changing the medium 24 h later. The cells were harvested 4 days after removal of 5-aza-dC for DNA and RNA extraction.
Quantitative real-time PCR analysis of basal CYP3A4, PXR and VDR mRNA levels
Total RNA extraction, cDNA synthesis and real-time PCR were carried out on the cells prepared above, by the same methods as described previously . mRNA levels of the CYP3A4 (exon 3-4, Hs01546612_m1), PXR (exon 5-6, Hs00243666_m1) and vitamin D receptor (VDR) (exon 10-11, Hs01045840_m1) were evaluated by TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA). In addition, the mRNA level of the PXR splicing variants (exon 1a-2) was also examined by SYBR Green assays using the following primers: 5'-GATTGTTCAAAGTGGACCCC-3'(forward) and 5'-TCCAGGAACAGACTCTGTGT-3'. The mRNA level of the above target genes was normalized to β-actin mRNA . All samples were analyzed in duplicate and average quantities of the gene transcripts were used for calculation. Deviation of the mRNA level of each sample was within 7% of the average.
DNA methylation analysis of the 6 colon cancer cell lines and 18 colon cancer samples
Primers used for DNA methylation analysis.
Primer sequence (5'-3')
Basal mRNA levels of the CYP3A4, PXR and VDR genes in the 6 colon cancer cell lines
Increased mRNA expression by 5-aza-dC treatment
DNA methylation status of the colon cancer cell lines
Profile of Microsatellite instability (MSI), mismatch repair (MMR) deficiency and promoter methylation in 6 colon cancer cell lines.
DNA methylation status of colon cancer tissue samples
No or slight methylation of the PXR exon 3 region was detected in the normal colon tissue samples by direct sequencing and the COBRA assay. The levels of methylation in the cancer tissues were mostly higher than those in the paired adjacent normal tissues (Figure 6b). By contrast, the CpG-rich sequence of the PXR promoter was partially methylated in normal tissues, and the degree of methylation was decreased in the paired cancer tissues (Figure 6c). The decreased level of the PXR promoter methylation suggested increased expression of the PXR gene during colorectal carcinogenesis. There were no differences in the clinicopathological findings between the colorectal cancers with PXR methylation and those without methylation.
In the present study, 6 colon cancer cell lines showed heterogeneous mRNA expression profiles and were able to be classified into two groups with respect to their basal levels of the PXR/CYP3A4 transcripts (high expression cells, LS180 and LoVo; low expression cells Caco-2, HT29, HCT116, and SW48). These results are consistent with previous studies, in which LS180 and Caco-2 cells were characterized as PXR-sufficient and PXR-deficient cells, respectively [16, 17].
Genetic polymorphisms in the regions that regulate transcription are often a major cause of inter-individual variability in the levels of transcripts. However, such polymorphisms have not been frequently observed in the human PXR or CYP3A4 genes, implying that certain epigenetic mechanisms are involved in the regulation of PXR and CYP3A4 expression. We found that the CpG-rich sequence within the PXR promoter region is methylated to different levels in high and low expression cells. Importantly, the magnitude of this promoter methylation was inversely associated with the levels of PXR and CYP3A4 expression. Furthermore, the levels of the PXR and CYP3A4 transcripts in low expression cells were mostly restored when DNA methylation was reversed by treatment with 5-aza-dC. Although this CpG-rich sequence did not strictly satisfy the criteria for a CpG island, the most affected CpG sites were located in a highly restricted region (segments 1 and 2) and these CpG sites were proximal to several putative transcription factor binding sites (such as Sp1 and hepatocyte nuclear factor 4 alpha) [18–20]. Therefore, PXR gene expression is most likely transcriptionally regulated by methylation of these promoter CpG sites.
CYP3A4 is transactivated by functional interplays with VDR-RXRα or PXR-PRMT1 [20–22]. CpG-island methylation of the VDR or PRMT1 promoter was not detected in these cell lines and the mRNA expression of VDR was not affected by 5-aza-dC treatment. These observations imply that DNA methylation of PXR, but not VDR or PRMT1, resulted in downregulation of the CYP3A4 mRNA in these colon cancer cells.
It is still uncertain whether re-expression of the CYP3A4 by 5-aza-dC treatment was due to the re-expression of some other genes than PXR. However, PXR must be a candidate for methylation and reduced expression of the PXR by promoter methylation, even if partially, contributes to downregulation of the CYP3A4. Indeed, several studies demonstrated that selective downregulation of the PXR by siRNA reduces the basal level of the CYP3A4 transcripts in a dose-dependent manner .
CpG islands in the exon 3 region were fully methylated throughout the cancer cell lines and most cancer tissues. Even after treatment of the cell lines with 5-aza-dC, no increase in the PXR mRNA levels was observed in the high-PXR expressing cell lines, LS180 and LoVo. This strongly suggests that in human colon cancer cells, the methylated CpG islands in the exon 3 play a much less role in the epigenetic regulation of PXR, instead, promoter methylation plays a pivotal role in its regulation. In contrast, Misawa et al. previously demonstrated a distinct methylation profile of neuroblastoma cells, in which mRNA expression of the PXR splicing variant (exon 1a-2) was specifically regulated by the methylation of the exon 3 region rather than promoter methylation . We found no marked difference in the levels of the PXR (exon 5-6) and PXR (exon 1a-2) transcripts in the colon cancer cells. Therefore, a tissue-specific DNA methylation profile is most likely involved in the transcriptional regulation of the PXR gene.
DNA methylation of the PXR promoter was detected in only 1 of the 18 colorectal cancer tissue samples. The results reflect the genuine DNA methylation status, because we examined pure cancerous and normal epithelia using crypt isolation and directly compared the DNA methylation status between paired epithelia. Therefore, a low level of PXR promoter methylation, which was observed in the high expression cells, appears to be a common feature of colorectal cancers. We also demonstrated that the level of PXR promoter methylation is decreased during carcinogenesis, since paired adjacent normal tissues mostly showed higher levels of PXR promoter methylation. We could not directly compare DNA methylation status with the PXR mRNA expression, because crypt isolation provided ethanol-fixed epithelia and it was difficult to obtain fresh mRNA samples. However, most cancer tissues exhibited a pattern of promoter methylation quite similar to that observed in cultured cells with high expression (LS180 and LoVo) (Figures 5 and 6c). Therefore, the association between promoter methylation and transcriptional silencing of the PXR gene is most likely applicable to primary colorectal cancers. As observed in the colon cancer cell lines, the decreased level of PXR promoter methylation most likely led to increased expression of PXR mRNA in the colorectal cancer tissues. These results are consistent with a recent study that showed strong expression of PXR mRNA in colon cancers, with great variability . In contrast, Ouyang et al. found that PXR expression was lost or greatly diminished in many colon cancers using histochemical analysis . Although the role of the altered PXR expression in colorectal carcinogenesis remains to be clarified, Zhou et al. demonstrated that PXR plays an antiapoptotic role in colon carcinogenesis by induction of multiple antiapoptotic genes .
We cannot rule out the possibility that alterations of the PXR methylation levels play direct roles in tumorigenesis, because certain oncogenes or tumor suppressor genes may be trascriptionally regulated by PXR. Partial methylation of the PXR observed in adjacent normal mucosa may be associated with "field defect" for carcinogenesis. However, numerous studies have demonstrated that ligand-binding activation or siRNA-mediated silencing of the PXR can affect the activity of metabolic enzymes including CYP3A4, without changes in the cell proliferation capacity. Therefore, we think that altered level of the PXR methylation does not provide a selective growth advantage during colorectal cancer progression.
Interestingly, overexpression of PXR in the colorectal cancer tissue samples was correlated with an increase in UDP glucuronosyl transferases UGT1A1, UGT1A9 and UGT1A10, and led to a marked chemoresistance to the active metabolite of irinotecan (CPT-11) . In addition, CYP3A4 and p-glycoprotein, which are transcriptionally activated by PXR, play important roles in intestinal first-pass metabolism and determine a drug's bioavailability. We hypothesized that PXR may play a key role in the colon cancer cell response to anticancer drugs by modulating expression of drug metabolizing enzymes and transporters including UGT1A, CYP3A4 and p-glycoprotein. Therefore, DNA methylation of the PXR promoter might be a good predictor of chemotherapy outcome and toxicity in colorectal cancers.
PXR promoter methylation is involved in the regulation of intestinal PXR and CYP3A4 expression. This methylation might be associated with the inter-individual variability of the drug response of colon cancer cells.
pregnane X receptor
vitamin D receptor
protein arginine methyltrasferase 1
combined bisulfite restriction analysis
This work was supported by a Grant-in-Aid for Scientific Research (C) (21590402) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.
- Zhang B, Xie W, Krasowski MD: PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics. 2008, 9: 1695-1709. 10.2217/146224220.127.116.115.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou C, Verma S, Blumberg B: The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal. 2009, 7: e001-PubMedPubMed CentralGoogle Scholar
- Kliewer SA, Goodwin B, Willson TM: The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002, 23: 687-702. 10.1210/er.2001-0038.View ArticlePubMedGoogle Scholar
- Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002, 54: 1271-1294. 10.1016/S0169-409X(02)00066-2.View ArticlePubMedGoogle Scholar
- von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT: Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004, 75: 172-183. 10.1016/j.clpt.2003.10.008.View ArticlePubMedGoogle Scholar
- Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS: Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999, 27: 804-809.PubMedGoogle Scholar
- Turan N, Katari S, Coutifaris C, Sapienza C: Explaining inter-individual variability in phenotype: Is epigenetics up to the challenge?. Epigenetics. 2010, 5: 16-19. 10.4161/epi.5.1.10557.View ArticlePubMedPubMed CentralGoogle Scholar
- Demura M, Bulun SE: CpG dinucleotide methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated aromatase activityMol Cell. Endocrinol. 2008, 283: 127-132.Google Scholar
- Misawa A, Inoue J, Sugino Y, Hosoi H, Sugimoto T, Hosoda F, Ohki M, Imoto I, Inazawa J: Methylation-associated silencing of the nuclear receptor 1I2 gene in advanced-type neuroblastomas, identified by bacterial artificial chromosome array-based methylated CpG island amplification. Cancer Res. 2005, 65: 10233-10242. 10.1158/0008-5472.CAN-05-1073.View ArticlePubMedGoogle Scholar
- Habano W, Gamo T, Sugai T, Otsuka K, Wakabayashi G, Ozawa S: CYP1B1, but not CYP1A1, is downregulated by promoter methylation in colorectal cancers. Int J Oncol. 2009, 34: 1085-1091. 10.3892/ijo_00000235.View ArticlePubMedGoogle Scholar
- Habano W, Sugai T, Nakamura S, Yoshida T: A novel method for gene analysis of colorectal carcinomas using a crypt isolation technique. Lab Invest. 1996, 74: 933-940.PubMedGoogle Scholar
- CpG Island Searcher. [http://cpgislands.usc.edu/]
- Takai D, Jones PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA. 2002, 99: 3740-1833745. 10.1073/pnas.052410099.View ArticlePubMedPubMed CentralGoogle Scholar
- Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J Mol Biol. 1987, 196: 261-282. 10.1016/0022-2836(87)90689-9.View ArticlePubMedGoogle Scholar
- Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997, 25: 2532-2534. 10.1093/nar/25.12.2532.View ArticlePubMedPubMed CentralGoogle Scholar
- Hartley DP, Dai X, Yabut J, Chu X, Cheng O, Zhang T, He YD, Roberts C, Ulrich R, Evers R, Evans DC: Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenet Genomics. 2006, 16: 579-599. 10.1097/01.fpc.0000220561.59972.7a.View ArticlePubMedGoogle Scholar
- Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, Ishizuka H, Kharasch E, Schuetz J, Schuetz E: Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001, 60: 1399-1406.PubMedGoogle Scholar
- Aouabdi S, Gibson G, Plant N: Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos. 2006, 34: 138-144. 10.1124/dmd.105.006064.View ArticlePubMedGoogle Scholar
- Kurose K, Ikeda S, Koyano S, Tohkin M, Hasegawa R, Sawada J: Identification of regulatory sites in the human PXR (NR1I2) promoter region. Mol Cell Biochem. 2006, 281: 35-43. 10.1007/s11010-006-0167-7.View ArticlePubMedGoogle Scholar
- Kurose K, Koyano S, Ikeda S, Tohkin M, Hasegawa R, Sawada J: 5' diversity of human hepatic PXR (NR1I2) transcripts and identification of the major transcription initiation site. Mol Cell Biochem. 2005, 273: 79-85. 10.1007/s11010-005-7757-7.View ArticlePubMedGoogle Scholar
- Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, Hunziker W: Two nuclear signalling pathways for vitamin D. Nature. 1993, 361: 657-660. 10.1038/361657a0.View ArticlePubMedGoogle Scholar
- Xie Y, Ke S, Ouyang N, He J, Xie W, Bedford MT, Tian Y: Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J Biol Chem. 2009, 284: 9199-9205. 10.1074/jbc.M806193200.View ArticlePubMedPubMed CentralGoogle Scholar
- Kojima K, Nagata K, Matsubara T, Yamazoe Y: Broad but distinct role of pregnane X receptor on the expression of individual cytochrome P450 in human hepatocytes. Drug Metab Pharmacokinet. 2007, 22: 276-286. 10.2133/dmpk.22.276.View ArticlePubMedGoogle Scholar
- Raynal C, Pascussi JM, Leguelinel G, Breuker C, Kantar J, Lallemant B, Poujol S, Bonnans C, Joubert D, Hollande F, Lumbroso S, Brouillet JP, Evrard A: Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol Cancer. 2010, 9: 46-10.1186/1476-4598-9-46.View ArticlePubMedPubMed CentralGoogle Scholar
- Ouyang N, Ke S, Eagleton N, Xie Y, Chen G, Laffins B, Yao H, Zhou B, Tian Y: Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br J Cancer. 2010, 102: 1753-1761. 10.1038/sj.bjc.6605677.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhou J, Liu M, Zhai Y, Xie W: The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol. 2008, 22: 868-880. 10.1210/me.2007-0197.View ArticlePubMedGoogle Scholar
- Wheeler JM, Beck NE, Kim HC, Tomlinson IP, Mortensen NJ, Bodmer WF: Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: The predominant role of hMLH1. Proc Natl Acad Sci USA. 1999, 96: 10296-10301. 10.1073/pnas.96.18.10296.View ArticlePubMedPubMed CentralGoogle Scholar
- Lind GE, Thorstensen L, Lovig T, Meling GI, Hamelin R, Rognum TO, Esteller M, Lothe RA: A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer. 2004, 3: 28-10.1186/1476-4598-3-28.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/81/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.